New combo therapy aims to boost organ preservation in aggressive rectal cancer

NCT ID NCT07551479

First seen May 01, 2026 · Last updated May 01, 2026

Summary

This phase 3 trial tests whether a shorter course of radiation followed by chemotherapy and an immunotherapy drug (Serplulimab) works better than the standard long-course chemoradiation for people with high-risk locally advanced rectal cancer. About 612 adults with specific high-risk features will be randomly assigned to one of two treatment plans. The goal is to see which approach leads to better 3-year survival without cancer events and possibly allows more patients to avoid surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.